The State Food and Drug Administration and other 8 departments recently jointly issued the “14th five year plan” for national drug safety and promoting high-quality development. The plan defines the main development objectives during the 14th Five Year Plan period. At the end of the 14th Five Year Plan period, the overall drug regulatory capacity is close to the international advanced level, the drug safety guarantee level continues to improve, and the people are more satisfied and assured with drug quality and safety. The regulatory environment supporting the high-quality development of the industry has been further optimized, the reform of the review and approval system has been continuously deepened, a batch of innovative drugs urgently needed in clinic have been approved, the listing of innovative drugs with clinical value has been accelerated, the global innovative drugs and Innovation Medical Management Co.Ltd(002173) devices applied in China have been listed in China as soon as possible, 2650 standards (items) for drugs, medical devices and cosmetics have been prepared and revised, and 480 guiding principles have been added.
(Financial Associated Press)
